Last reviewed · How we verify
Advanced renal cell carcinoma (RCC) after failure of prior therapy — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Axitinib (AG-013736) | axitinib-ag-013736 | Pfizer | tyrosine kinase inhibitor | vascular endothelial growth factor receptors (VEGFRs) |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Advanced renal cell carcinoma (RCC) after failure of prior therapy
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Advanced renal cell carcinoma (RCC) after failure of prior therapy:
- Advanced renal cell carcinoma (RCC) after failure of prior therapy treatment updates — RSS
- Advanced renal cell carcinoma (RCC) after failure of prior therapy treatment updates — Atom
- Advanced renal cell carcinoma (RCC) after failure of prior therapy treatment updates — JSON
Cite this brief
Drug Landscape (2026). Advanced renal cell carcinoma (RCC) after failure of prior therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/advanced-renal-cell-carcinoma-rcc-after-failure-of-prior-therapy. Accessed 2026-06-10.
Related
- Advanced renal cell carcinoma (RCC) after failure of prior therapy full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing